Table 1.
Patient characteristics
| Surgical resection (n = 33) | Chemotherapy (n = 39) | Total (N = 72) | |
|---|---|---|---|
| Age, years | 73 (60–88) | 67 (52–78) | 70 (52–88) |
| Gender, male (%) | 20 (61%) | 26 (67%) | 46 (64%) |
| DM+ | 10 (30%) | 17 (44%) | 27 (38%) |
| CEA, ng/mL | 3.02 (0.2–35.7) | 4.03 (0.4–93.8) | 4 (0.2–93.8) |
| CA19-9, IU/mL | 63.5 (0.6–2718) | 208 (0.6–7121) | 126.8 (0.6–7121) |
| Tumor site (head) | 15 (45%) | 17 (44%) | 32 (44%) |
| Tumor size, mm | 23 (13–60) | 30 (15–58) | 28 (13–60) |
| Stage (UICC) | |||
| I | 5 (15%) | 0 (0%) | 5 (7%) |
| II | 25 (76%) | 5 (13%) | 30 (42%) |
| III | 3(9%) | 15 (38%) | 18 (25%) |
| IV | 0 (0%) | 19 (49%) | 19 (26%) |
| Positive margin | 6 (19%) | ||
| Adjuvant therapy | 23 (70%) | ||
| cfDNA amount (ng/mL) | 15.5 (5–331) | 16.6 (7.4–645) | 15.9 (5–645) |
DM, diabetes mellitus; CEA, carcinoembryonic antigen; UICC, Union for International Cancer Control; cfDNA, cell-free DNA.